ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company has concluded a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program, which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.

Expert Comments:

Joseph Pantginis, ROTH Capital Partners (11/22/15)
"ImmunoCellular Therapeutics Ltd. provided a long-term update to the Phase 2 ICT-107 study showing a survival benefit continuing for ICT-107 in prospectively defined subgroups relative to control. Additionally, strong immune responses are shown to correlate with survival. . .we believe the Phase 3 (under special protocol assessment) should be able to show a survival benefit based on this targeting."

Jason McCarthy, Maxim Group (11/16/15)
"ImmunoCellular Therapeutics Ltd.'s ICT-107 Phase 3 trial for newly diagnosed glioblastoma is expected to take two years to enroll, with two interim looks planned. The first is a futility analysis after 30% of the patients have had events, and the second is an efficacy analysis after 66% of the patients have had events."

Jason McCarthy, Maxim Group (11/13/15)
"ImmunoCellular Therapeutics Ltd. announced a sponsored research agreement with MD Anderson Cancer Center to develop its Stem-to-T-cell program for developing novel stem-cell-based T-cells that target cancer antigens. . .this could be the critical key to unlocking the T-cell immune oncology space, and it gives us another way to think about attacking solid tumors. . .in addition, the company's dendritic cell (DC) vaccine platform (in a pivotal Phase 3 study in glioblastoma, ICT-107) could also factor in, because DCs drive T-cell responses. . .this could be a game-changing approach in immune oncology. Pay attention to what ImmunoCellular is doing."

Jason Kolbert, Maxim Group (11/11/15)
"ImmunoCellular Therapeutics Ltd. is progressing to initiate the ICT-107 Phase 3 trial (n=400) to evaluate dendritic cell-based cancer immunotherapy targeting newly diagnosed glioblastoma. The trial will include approximately 120 clinical sites in the U.S., Europe and Canada. . .we reiterate our belief in ICT-107 as a viable therapy for glioblastoma multiforme."

Joseph Pantginis, ROTH Capital Partners (11/11/15)
"ImmunoCellular Therapeutics Ltd. announced Q3/15 results, posting EPS of ($0.04), which was in line with our estimate. . .recall that in September 2015, the company received a $19.8M award from the California Institute for Regenerative Medicine geared toward partial funding of the ICT-107 Phase 3 study (under special protocol assessment), which is now screening patients. The first patient randomized into the study is expected by 2015E or early 2016."

Jason Kolbert, Maxim Group (9/24/15)
"ImmunoCellular Therapeutics Ltd. today announced it has been awarded $19.9M from the California Institute for Regenerative Medicine to fund the ICT-107 Phase 3 registration trial in patients with newly diagnosed glioblastoma. . .the company stays on track to execute its plan to initiate the Phase 3 ICT-107 trial (n=400) in Q4/15. . .we are excited to see ImmunoCellular continue to develop ICT-107 dendritic cell-based immunotherapy and progress towards its Phase 3 registration trial."

More Expert Comments

Experts Following This Company

Jerry Isaacson, Managing Director and Senior Analyst – LifeSci Advisors, LifeSci Capital
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Henry McCusker RegMed Investors
Joseph Pantginis, Senior Analyst – ROTH Capital Partners

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Pivotal Phase 3 registration trial of lead cancer immunotherapeutic ICT-107 in brain cancer to begin in 2015
Proprietary cancer immunotherapy development pipeline advancing; represents multiple partnering opportunities
Stem-to-T-cell program advancing toward clinical trials; novel immuno-oncology approach
catalyst Calendar
ImmunoCellular Therapeutics Ltd. Content